Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · IEX Real-Time Price · USD

48.85

+0.89 (1.86%)

At close: Apr 18, 2024, 4:00 PM

49.50

+0.65 (1.33%)

After-hours: Apr 18, 2024, 7:21 PM EDT

Janux Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	8.08	8.61	3.64	0	0
Revenue Growth (YoY)	-6.14%	136.79%	-	-	-
Gross Profit	8.08	8.61	3.64	0	0
Selling, General & Admin	26.14	22.26	10.33	1.8	0.77
Research & Development	54.92	53.44	26.24	3.04	3
Operating Expenses	81.06	75.7	36.57	4.84	3.77
Operating Income	-72.98	-67.09	-32.93	-4.84	-3.77
Interest Expense / Income	0	0	0	0.21	0.23
Other Expense / Income	-14.69	-4.03	-0.26	1.74	-
Pretax Income	-58.29	-63.06	-32.67	-6.78	-4
Net Income	-58.29	-63.06	-32.67	-6.78	-4
Shares Outstanding (Basic)	44	41	24	1	1
Shares Outstanding (Diluted)	44	41	24	1	1
Shares Change	6.14%	76.24%	2471.20%	36.71%	-
EPS (Basic)	-1.32	-1.52	-1.39	-7.41	-5.98
EPS (Diluted)	-1.32	-1.52	-1.39	-7.41	-5.98
Free Cash Flow	-52.43	-49.37	-18.46	-4.37	-3.83
Free Cash Flow Per Share	-1.19	-1.19	-0.78	-4.77	-5.72
Gross Margin	100.00%	100.00%	100.00%	-	-
Operating Margin	-902.87%	-779.04%	-905.39%	-	-
Profit Margin	-721.18%	-732.22%	-898.32%	-	-
Free Cash Flow Margin	-648.58%	-573.24%	-507.51%	-	-
EBITDA	-56.34	-62.22	-32.56	-6.57	-3.77
EBITDA Margin	-696.99%	-722.46%	-895.22%	-	-
Depreciation & Amortization	1.96	0.84	0.11	0.01	0.01
EBIT	-58.29	-63.06	-32.67	-6.58	-3.77
EBIT Margin	-721.18%	-732.22%	-898.32%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).